CD68 and inflammation: In this study, our results showed that intraperitoneally administered with iMSC-sEV remarkably ameliorated interstitial edema, reduced CD68 positive AMs migration, and improved the survival of CLP-induced septic lung injury rats in the model, confirming the ability of iMSC-sEV to mitigate airway inflammation and reduce lung injury under sepsis conditions.